Home > News > Headline News > Archive

Click on title to read the full article.

ASCO Special Article in JCO Encourages Researchers, Industry to Achieve More Meaningful Results

March 20, 2014

By ASCO.org

ASCO is urging cancer researchers, clinical trial sponsors, and drug developers to employ clinical trial designs that aim to significantly extend the lives of people with cancer. 

In a Special Article published today in the Journal of Clinical Oncology, ASCO outlines overall survival goals for cancer clinical trials in several diseases that researchers should aim for—and patients should expect. The recommendations, developed by the ASCO Cancer Research Committee working with other experts and cancer patient advocates, provide examples of "clinically meaningful outcomes" in four types of cancer: advanced pancreatic, lung, breast, and colon cancers.

Emerging Trends in Treating Her2+ Metastatic Breast Cancer

March 8, 2014

By Onc Live: Dr. Kimberly Blackwell

Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease. It remains the standard-of-care, first-line treatment for metastatic breast cancer. In less than a decade, the FDA has added three new drugs to the arsenal to treat advanced HER2-positive disease, while a growing number of clinical studies are evaluating dual-agent approaches to therapy through a variety of drug combinations. - See more at: http://www.onclive.com/conference-coverage/mbcc-2014/Blackwell-Explores-Emerging-Trends-in-Treating-HER2-Metastatic-BC#sthash.bEsUvLip.dpuf